Phaseline

Companies › Noucor Health

Noucor Health: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 1 Phase 1, 1 Phase 3, 1 Phase 2; Genitourinary, Immunology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Rupatadine
Platelet activating factor receptor antagonist; Histamine H1 receptor antagonist
PTAFR, HRH1Phase 1Renal Impairment; Rheumatoid Arthritis; Ulcerative Colitis–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06708520RupatadinePhase 1Renal ImpairmentGenitourinaryJul 2025
NCT07064707RupatadinePhase 2Ulcerative ColitisImmunologyJul 2026
NCT03770923RupatadinePhase 3Rheumatoid ArthritisImmunologyOct 2027

Targets

PTAFR (1) HRH1 (1)

Companies with the same targets

Shandong New Time Pharmaceutical

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.